ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease EEOCCCWG N. Colombo, C. Sessa, A. du Bois, J. Ledermann, W.G. McCluggage, I ... Int J Gynecol Cancer, 2019 | 1270* | 2019 |
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease EEOCCCWG N. Colombo, C. Sessa, A. du Bois, J. Ledermann, W.G. McCluggage, I ... Annals of Oncology 30 (5), 672-705, 2019 | 1270 | 2019 |
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research E Kipps, DSP Tan, SB Kaye Nature Reviews Cancer 13 (4), 273-282, 2013 | 635 | 2013 |
Mechanisms of transcoelomic metastasis in ovarian cancer DSP Tan, R Agarwal, SB Kaye The lancet oncology 7 (11), 925-934, 2006 | 592 | 2006 |
“BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and … DSP Tan, C Rothermundt, K Thomas, E Bancroft, R Eeles, S Shanley, ... Journal of Clinical Oncology 26 (34), 5530-5536, 2008 | 579 | 2008 |
Breast cancer molecular profiling with single sample predictors: a retrospective analysis B Weigelt, A Mackay, R A'hern, R Natrajan, DSP Tan, M Dowsett, ... The lancet oncology 11 (4), 339-349, 2010 | 498 | 2010 |
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients DSP Tan, C Marchió, RL Jones, K Savage, IE Smith, M Dowsett, ... Breast cancer research and treatment 111, 27-44, 2008 | 456 | 2008 |
Biomarkers for homologous recombination deficiency in cancer MM Hoppe, R Sundar, DSP Tan, AD Jeyasekharan JNCI: Journal of the National Cancer Institute 110 (7), 704-713, 2018 | 310 | 2018 |
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis C Marchio, MB Lambros, P Gugliotta, LV Di Cantogno, C Botta, B Pasini, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009 | 232 | 2009 |
First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors TA Yap, DSP Tan, A Terbuch, R Caldwell, C Guo, BC Goh, V Heong, ... Cancer discovery 11 (1), 80-91, 2021 | 205 | 2021 |
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies AL Wong, RA Soo, DS Tan, SC Lee, JS Lim, PC Marban, LR Kong, ... Annals of Oncology 26 (5), 998-1005, 2015 | 197 | 2015 |
Tiling path genomic profiling of grade 3 invasive ductal breast cancers R Natrajan, MB Lambros, SM Rodríguez-Pinilla, G Moreno-Bueno, ... Clinical Cancer Research 15 (8), 2711-2722, 2009 | 196 | 2009 |
Are triple-negative tumours and basal-like breast cancer synonymous? EA Rakha, DSP Tan, WD Foulkes, IO Ellis, A Tutt, TO Nielsen, ... Breast cancer research 9, 1-3, 2007 | 193 | 2007 |
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines E Arriola, C Marchio, DSP Tan, SC Drury, MB Lambros, R Natrajan, ... Laboratory investigation 88 (5), 491-503, 2008 | 190 | 2008 |
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas DSP Tan, MBK Lambros, S Rayter, R Natrajan, R Vatcheva, Q Gao, ... Clinical cancer research 15 (7), 2269-2280, 2009 | 189 | 2009 |
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers R Natrajan, B Weigelt, A Mackay, FC Geyer, A Grigoriadis, DSP Tan, ... Breast cancer research and treatment 121, 575-589, 2010 | 187 | 2010 |
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement A Mackay, B Weigelt, A Grigoriadis, B Kreike, R Natrajan, R A’hern, ... JNCI: Journal of the National Cancer Institute 103 (8), 662-673, 2011 | 168 | 2011 |
Ovarian clear cell adenocarcinoma: a continuing enigma DSP Tan, S Kaye Journal of clinical pathology 60 (4), 355-360, 2007 | 166 | 2007 |
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas DSP Tan, M Iravani, WG McCluggage, MBK Lambros, F Milanezi, ... Clinical Cancer Research 17 (6), 1521-1534, 2011 | 160 | 2011 |
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ A González-Martín, P Harter, A Leary, D Lorusso, RE Miller, B Pothuri, ... Annals of Oncology 34 (10), 833-848, 2023 | 145 | 2023 |